Physician profile
Amy Stricklin
NPI 1245712579
$4,630.30
in general payments reported to CMS, 2019-2025
26 companies · $627 in 2025
The $627 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,320 · 2022: $956 · 2023: $820 · 2024: $907 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.99 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,224.09 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $477.64 | 2021-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $413.36 | 2023-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $249.11 | 2021-2024 | Entyvio, Gattex |
| Horizon Therapeutics Plc | $132.61 | 2021 | |
| Janssen Scientific Affairs, LLC | $128.25 | 2022 | |
| Aimmune Therapeutics, INC. | $120.24 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $103.87 | 2022-2023 | Dupixent |
| Astellas Pharma US INC | $94.14 | 2021 | |
| Pfizer INC. | $85.88 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $80.03 | 2021-2024 | Linzess |
| Novartis Pharmaceuticals Corporation | $72.16 | 2021 | |
| Lilly USA, LLC | $52.59 | 2021-2025 | Omvoh |
| Celgene Corporation | $48.87 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $48.68 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $47.64 | 2021-2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $46.11 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $37.27 | 2025 | Iqirvo |
| Organon LLC | $35.67 | 2022-2023 | Hadlima |
| Intercept Pharmaceuticals, INC. | $25.99 | 2021 | |
| Ardelyx, INC. | $23.19 | 2025 | Ibsrela |
| Amarin Pharma, INC. | $18.75 | 2021 | |
| Glaxosmithkline, LLC. | $17.70 | 2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $17.61 | 2021 | |
| Dexcom, INC. | $15.12 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Stricklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.